Moison, Céline https://orcid.org/0009-0008-5381-3546
Mendoza-Sanchez, Rodrigo https://orcid.org/0009-0007-6962-7505
Gracias, Deanne
Schuetz, Doris A https://orcid.org/0000-0001-8615-9554
Spinella, Jean-François
Girard, Simon https://orcid.org/0000-0002-4593-5104
Thavonekham, Bounkham https://orcid.org/0009-0008-3479-3906
Chagraoui, Jalila
Durand, Aurélie
Fortier, Simon
MacRae, Tara
Bonneil, Eric
Rose, Yannick
Mayotte, Nadine
Boivin, Isabel
Thibault, Pierre https://orcid.org/0000-0001-5993-0331
Hébert, Josée https://orcid.org/0000-0002-2267-1353
Ruel, Réjean
Marinier, Anne https://orcid.org/0000-0002-0116-8345
Sauvageau, Guy https://orcid.org/0000-0002-4333-7266
Funding for this research was provided by:
Genome Canada (GC) / Genome Quebec (LSARP2017 - 13528)
Bristol Myers Squibb (LSARP2017 - 13528)
Genome Canada / Genome Quebec (GAPP - 6582)
RejuvenRx Inc (GAPP - 6582)
Canadian Government | Canadian Institutes of Health Research (MFE-158159)
Article History
Received: 9 October 2024
Revised: 14 March 2025
Accepted: 19 March 2025
First Online: 28 April 2025
Disclosure and competing interests statement
: The authors declare no competing interests.